SelectQuote reported consolidated revenue of $537.1 million for its fiscal second quarter, an 11.2% year‑over‑year increase that was driven by a 26% rise in its Healthcare Services segment, which generated $231 million, and a modest 2% growth in its Senior segment, which produced $262 million. The Healthcare Services growth reflects the rapid expansion of the SelectRx pharmacy platform, while the Senior segment’s modest gain comes amid a highly competitive Medicare Advantage market.
Net income for the quarter was $69.3 million, and earnings per share reached $0.26, beating consensus estimates of $0.22–$0.24 by $0.02–$0.04, or 8–18%. Adjusted EBITDA fell to $84.7 million from $87.5 million a year earlier, a 2.6% decline that reflects higher operating costs and the impact of a carrier‑driven marketing budget cut. The company’s adjusted EBITDA margin was 15.8%, down from 16.1% YoY, largely due to the mix shift toward lower‑margin legacy insurance products.
Management revised its full‑year outlook downward, lowering revenue guidance to $1.78–$1.82 billion from the previous $1.90–$1.95 billion range and cutting adjusted EBITDA guidance to $90–$100 million from $120–$150 million. The guidance cut was attributed to two partner‑driven headwinds: a national carrier’s decision to reduce marketing spend across all channels and a previously announced change in pharmacy benefit manager reimbursement rates that will compress margins in the Healthcare Services segment.
CEO Tim Danker emphasized that the guidance adjustment was a response to external factors rather than internal performance issues. He noted, “The carrier’s marketing budget cut and the PBM reimbursement change are partner‑driven challenges that do not reflect our operational execution. We remain confident in the long‑term economics of SelectRx and our ability to maintain profitability through disciplined cost management.”
Investors reacted negatively to the guidance revision, with market sentiment turning cautious despite the EPS beat. The downgrade in full‑year expectations has prompted a reassessment of the company’s near‑term growth trajectory, highlighting the sensitivity of SelectQuote’s legacy insurance business to partner actions and reimbursement dynamics.
The earnings report underscores a mixed outlook: while the high‑margin Healthcare Services segment continues to accelerate, the Senior segment’s growth is slowing and is exposed to carrier and reimbursement headwinds. The guidance cut signals management’s caution about near‑term demand and margin pressures, but the company’s strong cash flow generation and disciplined cost structure suggest it can navigate the current challenges while pursuing long‑term expansion of its pharmacy platform.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.